Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lynsay Brautnick (NPI 1548317340)

Field	Value
Entity Type	Individual
Organization	Lynsay Brautnick
Address	3232 N North Hills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 4, 2007

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology Physician in Fayetteville, AR, with an NPI enumerated on 2007-01-04 (~19 years ago), indicating long-term Medicare participation and continuity of practice in the market. The sustained enrollment period supports experience in oncology service delivery and suggests established referral and treatment workflows typical for a veteran specialist.

Medicare is effectively the sole public payer on file: lifetime Medicare revenue is $2M while there is no Medicaid billing on file, making this provider functionally single-payer (Medicare)-focused in the available dataset. Analysts should treat Medicaid as absent when modeling payer mix and local safety-net exposure.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 48.7% of the provider’s total Medicare revenue, signaling dependence on a small set of high-revenue oncology drugs and services. Those top drivers include J9271 (pembrolizumab), J9144 (daratumumab/hyaluronidase-fihj), and J1561 (immune globulin), consistent with a drug-centric oncology infusion practice.

The code mix and descriptions point to an infusion- and imaging-heavy oncology practice: high-revenue chemotherapy/oncology drug codes (J9271, J9144, J9299, J1561, J1561) and related infusion procedure codes (96413, 96365, 96367) are prominent, while advanced imaging (78815, 78816, A9552) and CT services (74178, 71260) appear as meaningful revenue contributors, indicating in-house or closely integrated diagnostic imaging for staging and treatment monitoring.

Competitive standing varies by code: for pembrolizumab (J9271) the provider ranks #1338 of 1841 (27th percentile), which the source frames as typical/unremarkable national volume, whereas for daratumumab (J9144) the provider ranks #314 of 615 (49th percentile), closer to the median national participant. Several biologic and biosimilar drug codes (e.g., J1561 rank #61 of 180 at the 66th percentile; Q5115 rank #45 of 79 at the 44th percentile) show modest to middle-tier national positioning, implying the practice is a regular but not dominant national user of those therapies.

There are notable national outliers in certain non-drug services: 99215 visits rank #1873 of 145531 providers nationally (99th percentile) and CT abdomen/pelvis without and with contrast (74178) ranks #152 of 11397 (99th percentile), both labeled in the data as extreme outliers and far above typical national volume. These two high-percentile service lines suggest unusually high utilization of high-complexity office visits and abdomen/pelvis CTs relative to peers and may reflect patient complexity, local referral patterns, or bundled service arrangements.

Most chemotherapy administration and supportive care procedure volumes are within typical national ranges: 96413 ranks in the 88th percentile, 96365 and 96367 are in the 83rd–89th percentile ranges, and many drug administration codes are described as typical/unremarkable. This pattern indicates the practice manages routine infusion throughput at scale consistent with many community oncology practices rather than being an outlier across the board.

Laboratory testing volumes (80053 CMP and 85025 CBC) are relatively high in national rank (97th percentiles for both), reflecting substantial routine monitoring tied to active oncology treatment. These lab patterns are consistent with frequent systemic therapy management and ongoing toxicity surveillance for an active infusion practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

115 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	8,600	$40	$361.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,920	$40	$293K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	5,930	$40	$225.4K
J9299	Injection, nivolumab, 1 mg	8,760	$20	$201.5K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	110	$1,020	$115.7K
J0897	Injection, denosumab, 1 mg	5,040	$20	$90.7K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,440	$40	$85.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	510	$120	$62.6K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	2,110	$20	$50.6K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	40	$1,020	$41.7K

Showing 1–10 of 115

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 115 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Lynsay Brautnick — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

115 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	39	40	20,700	$40	$896.3K
J9299	25	30	15,660	$20	$432.9K
J9144	8	10	10,530	$40	$361.9K
G6015	12	10	840	$240	$357K
J1561	7	10	5,930	$40	$216.4K
Q5115	15	20	2,800	$30	$95.9K
J0897	52	160	2,580	$20	$89.7K
78815	45	100	90	$550	$83.7K
Q5118	5	10	2,110	$20	$64.3K
J0885	31	40	4,070	$10	$38K

Showing 1–10 of 115

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lynsay Brautnick, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Lynsay Brautnick, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

Lynsay Brautnick — Billing Profile & Reimbursement Data

Sign up for Lynsay Brautnick — Billing Profile & Reimbursement Data policy alerts

Lynsay Brautnick — Billing Profile & Reimbursement Data

Sign up for Lynsay Brautnick — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References